Innate Pharma SA, a clinical-stage biotechnology company headquartered in Marseille, France, continues to make significant strides in the healthcare sector, particularly within the realm of biotechnology. Founded in 1999, Innate Pharma SA has established itself as a key player in the development of therapeutic antibodies aimed at treating various forms of cancer. The company’s innovative approach to oncology treatment is evident in its diverse portfolio of therapeutic antibodies, which are designed to target specific cancer-related pathways and mechanisms.
One of the standout products in Innate Pharma’s pipeline is IPH4102, a therapeutic antibody developed for the treatment of cutaneous T-cell lymphomas. This product exemplifies the company’s commitment to addressing complex and challenging cancer types. Additionally, Monalizumab, another significant offering, is being explored for various cancer indications and stages, showcasing Innate Pharma’s broad approach to oncology treatment.
The company’s research extends to IPH5401, which targets C5a receptors on myeloid-derived suppressor cells and neutrophils, potentially offering new avenues for cancer therapy. Lirilumab, a human monoclonal antibody, is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands, further illustrating the company’s innovative strategies in immunotherapy.
Innate Pharma’s portfolio also includes IPH52 and IPH53, anti-CD39 and anti-CD73 antibodies, respectively, both of which are part of the company’s immuno-oncology initiatives. Additionally, IPH4301, an anti-MICA/B therapeutic antibody, is being developed to treat oncology, highlighting the company’s focus on novel therapeutic targets.
Beyond its clinical-stage products, Innate Pharma SA offers Lumoxiti, a commercial-stage oncology product used in the treatment of hairy cell leukemia. This product underscores the company’s ability to bring innovative treatments from the research phase to market, providing tangible benefits to patients.
Innate Pharma SA’s strategic collaborations and licensing agreements further bolster its position in the biotechnology landscape. The company has established licensing agreements with major pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. These partnerships enable Innate Pharma to leverage the resources and expertise of these industry giants, facilitating the development and commercialization of its therapeutic products.
Additionally, Innate Pharma collaborates clinically with MedImmune, enhancing its research capabilities and expanding its reach in the oncology field. This collaboration is a testament to the company’s commitment to advancing cancer treatment through strategic partnerships.
Innate Pharma SA’s journey to becoming a publicly traded company began in 2006 when it went public through an IPO on the NYSE Euronext Paris. This milestone marked a significant step in the company’s growth, providing it with the capital necessary to expand its research and development efforts.
As of February 16, 2026, Innate Pharma SA’s close price stood at 1.442 EUR, with a market capitalization of 135,150,976 EUR. Despite a negative price-to-earnings ratio of -2.623, the company’s focus on innovative cancer therapies and strategic partnerships positions it well for future growth and success in the biotechnology sector.
Innate Pharma SA’s dedication to developing cutting-edge therapeutic antibodies and its strategic collaborations underscore its role as a leader in the biotechnology industry. As the company continues to advance its research and expand its product offerings, it remains committed to improving cancer treatment and enhancing patient outcomes worldwide.
